GlobeNewswire Inc.··Not SpecifiedVesicor Therapeutics Appoints Veteran Biotech Executive Tolentino as CEO Ahead of SPAC Merger
Vesicor Therapeutics names Michael Tolentino as CEO effective March 2026, succeeding founder Luo Feng. Leadership transition precedes de-SPAC merger completion and 2027 FDA submission.
BKHABKHARBKHAUSPAC mergerCEO appointment